Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer

被引:35
作者
Bott, Matthew J.
Patel, Aalok P.
Crabtree, Traves D.
Morgensztern, Daniel
Robinson, Clifford G.
Colditz, Graham A.
Waqar, Saiama
Kreisel, Daniel
Krupnicka, A. Sasha
Patterson, G. Alexander
Broderick, Stephen
Meyers, Bryan F.
Puri, Varun
机构
[1] Washington Univ, Sch Med, Div Cardiothorac Surg, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Div Oncol, Dept Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA
关键词
GROUP PHASE-II; CHEST RADIOTHERAPY; CHEMORADIOTHERAPY; SURGERY; CHEMOTHERAPY; CISPLATIN; ETOPOSIDE; THERAPY; IMPACT;
D O I
10.1016/j.athoracsur.2015.02.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The role of multimodality therapy in stage IIIB non-small cell lung cancer (NSCLC) remains inadequately studied. Although chemoradiation is currently the mainstay of treatment, randomized trials evaluating surgical intervention are lacking, and resection is offered selectively. Methods. Data from patients with clinical stage IIIB NSCLC (T4N2 or any N3) undergoing definitive multimodality therapy were obtained from the National Cancer Database (NCDB). Multivariable Cox regression models were fitted to evaluate variables influencing overall survival (OS). Results. From 1998 to 2010, 7,459 patients with clinical stage IIIB NSCLC were treated with definitive chemoradiation (CR group), whereas 1,714 patients underwent chemotherapy, radiation, and surgical intervention in any sequence (CRS group). CRS patients were more likely to be younger and white and have slightly smaller tumors (all p < 0.01). There was no difference in Charlson Comorbidity Index (CCI) between the groups (p = 0.5). In the CRS group, 79% of patients received neoadjuvant therapy. Thirty-day surgical mortality was 3%. Factors associated with improved OS in multivariate analysis included younger age, female sex, decreased CCI, smaller tumor size, and surgical resection (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.52-0.63). Among patients treated with surgical intervention, incomplete resection was associated with decreased OS (HR, 1.52; 95% CI, 1.20-1.92). Median OS was longer in the CRS group (25.9 months versus 16.3 months; p < 0.001). Propensity matched analysis on 631 patient pairs treated with CRS versus CR confirmed these findings (median OS, 28.9 versus 17.2 months; p < 0.001). Conclusions. Surgical resection as a part of multimodality therapy may be associated with improved OS in highly selected patients with stage IIIB NSCLC. Multidisciplinary evaluation of these patients is critical. (C) 2015 by The Society of Thoracic Surgeons
引用
收藏
页码:1921 / 1928
页数:8
相关论文
共 18 条
  • [1] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805
    ALBAIN, KS
    RUSCH, VW
    CROWLEY, JJ
    RICE, TW
    TURRISI, AT
    WEICK, JK
    LONCHYNA, VA
    PRESANT, CA
    MCKENNA, RJ
    GANDARA, DR
    FOSMIRE, H
    TAYLOR, SA
    STELZER, KJ
    BEASLEY, KR
    LIVINGSTON, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1880 - 1892
  • [2] Concurrent cisplatin, etoposide, and chest radiotherapy in Pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019
    Albain, KS
    Crowley, JJ
    Turrisi, AT
    Gandara, DR
    Farrar, WB
    Clark, JI
    Beasley, KR
    Livingston, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) : 3454 - 3460
  • [3] American Cancer Society, 2014, CANC FACTS FIG 2014
  • [4] Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival
    Decaluwe, Herbert
    De Leyn, Paul
    Vansteenkiste, Johan
    Dooms, Christophe
    Van Raemdonck, Dirk
    Nafteux, Philippe
    Coosemans, Willy
    Lerut, Toni
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (03) : 433 - 439
  • [5] Edge S.B., 2010, AJCC cancer staging manual, V649
  • [6] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
  • [7] Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer
    Grunenwald, DH
    André, F
    Le Péchoux, C
    Girard, P
    Lamer, C
    Laplanche, A
    Tarayre, M
    Arriagada, R
    Le Chevalier, T
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (04) : 796 - 802
  • [8] Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer
    Ichinose, Y
    Fukuyama, Y
    Asoh, H
    Ushijima, C
    Okamoto, T
    Ikeda, J
    Okamoto, J
    Sakai, M
    [J]. ANNALS OF THORACIC SURGERY, 2003, 76 (06) : 1810 - 1814
  • [9] Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    Kelly, Karen
    Chansky, Kari
    Gaspar, Laurie E.
    Albain, Kathy S.
    Jett, James
    Ung, Yee C.
    Lau, Derick H. M.
    Crowley, John J.
    Gandara, David R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2450 - 2456
  • [10] Results of Trimodality Therapy in Patients With Stage IIIA (N2-Bulky) and Stage IIIB Non-Small-Cell Lung Cancer
    Li, Jian
    Dai, Chun-Hua
    Yu, Li-Chao
    Chen, Ping
    Li, Xiao-Qin
    Shi, Shun-Bing
    Wu, Jing-Rong
    [J]. CLINICAL LUNG CANCER, 2009, 10 (05) : 353 - 359